These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33979261)

  • 1. Validity and reliability of the QLQ-MY20 module for assessing the health-related quality of life in Brazilians with multiple myeloma.
    Malta JS; Silveira LP; Drummond PLM; Costa NL; Dos Santos RMM; Reis IA; Reis AMM; de Pádua CAM
    Curr Med Res Opin; 2021 Jul; 37(7):1163-1169. PubMed ID: 33979261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability and Validity of an Iranian Version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Multiple Myeloma: the EORTC QLQ-MY20.
    Ahmadzadeh A; Yekaninejad MS; Saffari M; Pakpour AH; Aaronson NK
    Asian Pac J Cancer Prev; 2016; 17(1):255-9. PubMed ID: 26838220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the Quality of Life Multiple Myeloma Module Questionnaire (QLQ-MY20) in Portuguese myeloma patients.
    Graça Pereira M; Ferreira G; Pereira M; Faria S; Bacalhau R; Monteiro S; Fernandes B; Vilaça M
    Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13128. PubMed ID: 31273859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development.
    Forde K; Cocks K; Wells JR; McMillan I; Kyriakou C;
    Blood Cancer J; 2023 May; 13(1):79. PubMed ID: 37193682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.
    Dachs LR; Gaisán CM; Bustamante G; López SG; García EG; Persona EP; González-Calle V; Auzmendi MS; Pérez JMA; González Montes Y; Ríos Tamayo R; de Miguel Llorente D; Bernal LP; Mayol AS; Caro CC; Grande M; Fernández-Nistal A; Naves A; Miguel EMOS
    Leuk Lymphoma; 2023; 64(11):1847-1856. PubMed ID: 37539698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument.
    Espinoza-Zamora JR; Portilla-Espinosa CM; Labardini-Méndez JR; Cervera E; Niesvisky R; Oñate-Ocaña LF
    Ann Hematol; 2015 Jun; 94(6):1017-24. PubMed ID: 25563595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
    Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
    Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma.
    Kontodimopoulos N; Samartzis A; Papadopoulos AA; Niakas D
    ScientificWorldJournal; 2012; 2012():842867. PubMed ID: 22919356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma.
    Cocks K; Cohen D; Wisløff F; Sezer O; Lee S; Hippe E; Gimsing P; Turesson I; Hajek R; Smith A; Graham L; Phillips A; Stead M; Velikova G; Brown J;
    Eur J Cancer; 2007 Jul; 43(11):1670-8. PubMed ID: 17574838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life and use of medication with anticholinergic activity in patients with multiple myeloma.
    de Lima MSR; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
    Support Care Cancer; 2023 Jun; 31(7):379. PubMed ID: 37278732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability and validity of the Amharic version of European Organization for Research and Treatment of cervical Cancer module for the assessment of health related quality of life in women with cervical cancer in Addis Ababa, Ethiopia.
    Araya LT; Gebretekle GB; Gebremariam GT; Fenta TG
    Health Qual Life Outcomes; 2019 Jan; 17(1):13. PubMed ID: 30642359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translation and validation of EORTC QLQ-H&N 35 into Moroccan Arabic for ENT head and neck cancer patients in Morocco.
    Ouattassi N; Benmansour N; ElFakir S; Nejjari C; Alami MN
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2727-34. PubMed ID: 26506999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients.
    Sully K; Trigg A; Bonner N; Moreno-Koehler A; Trennery C; Shah N; Yucel E; Panjabi S; Cocks K
    Eur J Haematol; 2019 Nov; 103(5):500-509. PubMed ID: 31444815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of therapeutic regimens and polypharmacy on health-related quality of life of people with multiple myeloma: a cross-sectional study in Belo Horizonte, Brazil.
    Malta JS; Drummond PLM; Silveira LP; Costa NL; Santos RMMD; Machado CJ; Reis AMM; de Pádua CAM
    Curr Med Res Opin; 2022 Aug; 38(8):1275-1283. PubMed ID: 35083943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Questionnaire to assess quality of life in patients with breast cancer - Validation of the Chinese version of the EORTC QLQ-BR 53.
    Zhang Z; Zhang X; Wei L; Lin Y; Wu D; Xie S; Yue L; Tian J; Zhang Y; Song Q; Woo SM; Miller AR; Luo L; Zhang L
    Breast; 2017 Apr; 32():87-92. PubMed ID: 28068605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France.
    Despiégel N; Touboul C; Flinois A; Saba G; Suzan F; Gonzalez-McQuire S; Bonnetain F
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e13-e28. PubMed ID: 30292736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Brazilian Version of the Edmonton Symptom Assessment System (ESAS) Is a Feasible, Valid and Reliable Instrument for the Measurement of Symptoms in Advanced Cancer Patients.
    Paiva CE; Manfredini LL; Paiva BS; Hui D; Bruera E
    PLoS One; 2015; 10(7):e0132073. PubMed ID: 26154288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.
    Sztankay M; Aaronson NK; Arraras JI; Basso U; Bumbasirevic U; Efficace F; Giesinger JM; Johnson CD; van Leeuwen M; Oberguggenberger AS; Sosnowski R; Young T; Holzner B;
    BMC Cancer; 2018 Nov; 18(1):1104. PubMed ID: 30419889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric properties of the Chilean version of the quality of life questionnaire for multiple myeloma.
    Lorca LA; Sacomori C; Peña C; Barrera C; Salazar M; Leão I; Valladares X; Rojas C
    Rev Bras Enferm; 2024; 77(1):e20230100. PubMed ID: 38716906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation study of the EORTC information questionnaire (EORTC QLQ-INFO25) in Iranian cancer patients.
    Asadi-Lari M; Ahmadi Pishkuhi M; Almasi-Hashiani A; Safiri S; Sepidarkish M
    Support Care Cancer; 2015 Jul; 23(7):1875-82. PubMed ID: 25475735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.